Literature DB >> 19494840

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation.

A Palumbo1, O Sezer, R Kyle, J S Miguel, R Z Orlowski, P Moreau, R Niesvizky, G Morgan, R Comenzo, P Sonneveld, S Kumar, R Hajek, S Giralt, S Bringhen, K C Anderson, P G Richardson, M Cavo, F Davies, J Bladé, H Einsele, M A Dimopoulos, A Spencer, A Dispenzieri, T Reiman, K Shimizu, J H Lee, M Attal, M Boccadoro, M Mateos, W Chen, H Ludwig, D Joshua, J Chim, V Hungria, I Turesson, B G M Durie, S Lonial.   

Abstract

In 2005, the first guidelines were published on the management of patients with multiple myeloma (MM). An expert panel reviewed the currently available literature as the basis for a set of revised and updated consensus guidelines for the diagnosis and management of patients with MM who are not eligible for autologous stem cell transplantation. Here we present recommendations on the diagnosis, treatment of newly diagnosed non-transplant-eligible patients and the management of complications occurring during induction therapy among these patients. These guidelines will aid the physician in daily clinical practice and will ensure optimal care for patients with MM.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19494840     DOI: 10.1038/leu.2009.122

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  41 in total

Review 1.  Novel Induction Regimens in Multiple Myeloma.

Authors:  Karie D Runcie; Tomer M Mark
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

Review 2.  How best to use new therapies in multiple myeloma.

Authors:  David Dingli; S Vincent Rajkumar
Journal:  Blood Rev       Date:  2010-04-01       Impact factor: 8.250

3.  Autologous Hematopoietic Stem Cell Transplantation-10 Years of Data From a Developing Country.

Authors:  Natasha Ali; Salman Naseem Adil; Mohammad Usman Shaikh
Journal:  Stem Cells Transl Med       Date:  2015-06-01       Impact factor: 6.940

4.  Elderly man with a pulmonary mass and osteolytic lesions: is it primary pulmonary plasmacytoma or multiple myeloma with an extramedullary pulmonary nodule?

Authors:  Aung Myint Tun; Yu Yu Thar; Aye Min Soe; Ei Ei Naing
Journal:  BMJ Case Rep       Date:  2016-06-29

Review 5.  Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation.

Authors:  J F San Miguel; M-V Mateos
Journal:  Leuk Suppl       Date:  2013-05-08

Review 6.  Challenges in multiple myeloma diagnosis and treatment.

Authors:  S Girnius; N C Munshi
Journal:  Leuk Suppl       Date:  2013-05-08

Review 7.  International Myeloma Working Group consensus statement for the management, treatment, and supportive care of patients with myeloma not eligible for standard autologous stem-cell transplantation.

Authors:  Antonio Palumbo; S Vincent Rajkumar; Jesus F San Miguel; Alessandra Larocca; Ruben Niesvizky; Gareth Morgan; Ola Landgren; Roman Hajek; Hermann Einsele; Kenneth C Anderson; Meletios A Dimopoulos; Paul G Richardson; Michele Cavo; Andrew Spencer; A Keith Stewart; Kazuyuki Shimizu; Sagar Lonial; Pieter Sonneveld; Brian G M Durie; Philippe Moreau; Robert Z Orlowski
Journal:  J Clin Oncol       Date:  2014-01-13       Impact factor: 44.544

8.  Multiple myeloma: an update.

Authors:  Khalil Al-Farsi
Journal:  Oman Med J       Date:  2013-01

9.  Use and impact of herpes zoster prophylaxis in myeloma patients treated with proteasome inhibitors.

Authors:  Siyang Leng; Suzanne Lentzsch; Yanhan Shen; Wei-Yann Tsai; Jason Dennis Wright; Dawn Lauryn Hershman; Alfred I Neugut
Journal:  Leuk Lymphoma       Date:  2018-02-02

10.  Impact of the treatment-free interval on health-related quality of life in patients with multiple myeloma: a UK cross-sectional survey.

Authors:  S Acaster; S Gaugris; G Velikova; K Yong; A J Lloyd
Journal:  Support Care Cancer       Date:  2012-08-12       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.